Navigation Links
Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
Date:6/11/2012

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. These findings were presented in an oral presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) on Monday, June 11 from 6:15 - 6:30 PM EDT.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"There is a real need for faster-acting mealtime insulins. By accelerating the absorption and action of prandial insulins, rHuPH20 may help reduce mealtime glucose fluctuations that make managing diabetes difficult," said Irl B. Hirsch, M.D., Professor of Medicine, Diabetes Treatment and Teaching Chair, University of Washington School of Medicine. "This faster-in, faster-out profile may also attenuate the risk of hypoglycemia. In this study, improved control of mealtime glucose significantly reduced hypoglycemic events in patients receiving treatments with the rHuPH20 enzyme. The data further indicated that Halozyme's ultrafast insulin formulations moderate glucose swings, thus more closely mimicking the effects of endogenous insulin and, if approved, could ultimately help patients with diabetes live healthier lives."

The study compared two rapid acting insulin analog products (lispro or aspart), formulated with rHuPH20 (lispro-PH20 and aspart-PH20, each an Analog-PH20), to an active comparator (lispro alone). The study me
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
2. Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances
3. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
4. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
5. Stereotaxis Reports Improved First Quarter 2012 Financial Results
6. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
7. Celleration, Inc. Announces First Patient Enrollment in In-Balance VLU Randomized Control Trial
8. Accident Fund Holdings Aims to Improve Control of Drug Utilization and Quality of Care with Change in Pharmacy Benefit Manager
9. DebMed® to Debut Benefits of Worlds First Electronic Hand Hygiene Compliance Monitoring System Using the WHO Five Moments at Annual Infection Control Conference
10. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/27/2015)... The Radiology Business Management Association ... applied business information and intelligence, is proud to announce ... newsletter for its more than 2,000 members. , “RBMA ... news sources in that it is exclusively devoted to ... radiology. The newsletter is produced in cooperation with Thorn ...
(Date:4/27/2015)... Doping has been around sports for years ... continue to capture the public’s imagination, but so-called smart ... performance enhancement along with new ethical considerations. In an ... Anjan Chatterjee of Pennsylvania Hospital and the ... of these enhancements in sports. , Chatterjee studies the ...
(Date:4/27/2015)... 2015 Jvion, the Atlanta-based leader in ... and recognized as one of the top 40 fastest ... is presented by the Atlanta Business Chronicle, honors Atlanta’s ... status as an economic capital and employment hub. , ... spurred by the growing need to improve healthcare quality ...
(Date:4/26/2015)... Indianapolis, Indiana (PRWEB) April 26, 2015 ... network service provider announces that Brotherhood Mutual Insurance Company ... Daniel Armstrong, Manager of Network Infrastructure at Brotherhood Mutual ... value and the service reliability Brotherhood Mutual needed. ... route diversity, and IFN worked with us to ensure ...
(Date:4/26/2015)... This annual celebration is one of the ... include a spectacular collection of vendors offering distinctive gifts ... incense, chimes, vases, candleholders, fleece throws, trivets, jewelry and ... collection of vendors, guests will have the opportunity to ... Jimmie Jazz Band. , “We are ecstatic to ...
Breaking Medicine News(10 mins):Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3Health News:Jvion Named to Top 40 Atlanta 2015 Pacesetters 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2
... Pays Cash When You Are Sick or Hurt?COLUMBUS, Ga., March 2 ... Aflac Duck as the mystery benefactor to policyholders who ... humorously shows how Aflac pays cash benefits when a medical ... night in a dark parlor. A group of friends is comforting ...
... March 2 DATATRAK International, Inc. (Nasdaq: ... global eClinical solutions for the clinical trials industry, today ... of Research and Development. In his role as DATATRAK,s ... to Raymond J. Merk, DATATRAK,s Chief Financial Officer and ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a ... Plus (R) brand, today announced that members of its executive ... Institutional Investors Conference on Monday, March 9, 2009 at 8:40 ... The JW Marriott Grande Lakes Hotel in Orlando, Fla. ...
... study of children ages 8-11 years shows contact ... Athletic Competence, and Social Acceptance , JACKSONVILLE, ... benefits to children beyond simply correcting their nearsightedness ... physical appearance, acceptance among friends, and ability to ...
... Workplace Awards, Ten Honored for Best PracticesWASHINGTON, March ... can be felt across all industries, workplaces that ... times reap rewards for employer and employees alike, ... Psychologically Healthy Workplace Awards ceremony yesterday. Five organizations ...
... its 15,000th wish this summer , ... Pickering, ON, (PRWEB) March 2, ... three and 17 are diagnosed with a life-threatening illness. Every day more ... the efforts of The Children,s Wish Foundation of Canada and ...
Cached Medicine News:Health News:New Aflac Commercial Asks, 'Who Dun It?' 2Health News:New Aflac Commercial Asks, 'Who Dun It?' 3Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 2Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 2Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: